Kindly refer the attachment

4th August 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Dalal Street Bandra-Kurla Complex, Bandra (E) Mumbai 400 001 Mumbai 400 051 Scrip Code: 500674 Symbol: SANOFI Sub: Outcome of the Board Meeting of the Company Dear Sirs/Madam, We refer to our intimation dated 20th July 2026, we hereby inform you that the Board of Directors at its meeting held today i.e., Tuesday, 4th August 2026, inter- alia: 1. Considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026. Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Results for the quarter and half year ended 30th June 2026, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). A press release in this regard has also been enclosed. Extract of the aforesaid Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations. The aforesaid Financial Results will also be available on the Company’s website on Financial results - Sanofi India. 2. Pursuant to Regulation 30 of the Listing Regulations, the Board of Directors have approved: a. Re-constitution of the following Committees with effect from 1st October 2026: i. Stakeholders Relationship Committee: Sr No Name of the Member Category Position in Committee 1 Mr. Siraj Chaudhry Independent Director Chairman 2 Mr. Deepak Arora Managing Director Member 3 Ms. Sudipta Chakraborty Whole Time Director Member Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number : L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com ii. Risk Management Committee: Sr No Name of the Member Category Position in Committee 1 Ms. Rajani Kesari Independent Director Chairperson 2 Mr. Siraj Chaudhry Independent Director Member 3 Mr. Deepak Arora Managing Director Member 4 Mr. Mahadev Gawade Whole Time Director Member b. Pursuant to the Regulation 30(5) of the Listing Regulations, in view of stepping down of Mr. Rachid Ayari as Whole Time Director and Chief Financial Officer with effect from the close of business hours on 30th September 2026, his name will be deleted from the list of Key Managerial Personnels authorised to determine materiality of an event or information and making disclosures to the Stock Exchanges. The meeting of Board of Directors commenced at 4:00 p.m. and concluded at 6:58 p.m. Please take the above information on record. Thanking you, Yours faithfully For Sanofi India Limited Haresh Vala Company Secretary and Compliance Officer Membership No.: A18246 Encl: a/a Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number : L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com Press Release Sanofi India delivers strong Q2 2026 performance, Led by double digit growth in Diabetes Portfolio and a Robust Profit Momentum Mumbai, August 4th, 2026 Sanofi India Limited announced its financial results for the quarter ended on June 30th, 2026, reporting domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The Insulin portfolio continued its strong trajectory, delivering double-digit growth of 14% for the second consecutive quarter, reinforcing Sanofi's leadership position in the basal analog market with a 58% value market share and 61% volume market share*. Growth was powered by Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®, the premium offering in the premix diabetes space. The public sector business accelerated by 70%, with the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, further strengthening Sanofi's footprint in the diabetes injectable space. Strategic partnerships in Cardiovascular, Oral anti-Diabetes and Central Nervous System segments have established a strong foundation, meeting expectations for market reach expansion. Partnership revenues grew 2% in Q2 2026, with continued return on investment from an expanded commercial footprint Export sales remained broadly stable, demonstrating the resilience of Sanofi India's international operations amid global headwinds. Profits before tax and exceptional items increased 19% to INR 112 crores, compared to INR 94 crores in the second quarter 2025. Profit before tax as a percentage of net sales improved to 27% in Q2 2026, up from 24% in Q2 2025. This improvement reflects a favorable product mix and disciplined cost management through operational efficiencies, with operating expenses (employee cost + other expenses) declining 5% compared to the second quarter of 2025. Deepak Arora Managing Director "Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double-digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business. Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a modernized go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long-term value creation is firmly in place. As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents." * Source for market share: IQVIA MAT June 2026 Sanofi in India Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people’s lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Sanofi’s India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company’s global pipeline. Sanofi India’s world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally. Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices from 2019-2024, Sanofi’s local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL). For more information, visit: www.sanofi.com/en/india, LinkedIn and X. Media Relations Vinifer Gandhi | vinifer.gandhi@sanofi.com Price Waterhouse & Co Chartered Accountants LLP Review Report The Board of Directors Sanofi India Limited CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 1. We have reviewed the unaudited financial results of Sanofi India Limited (the “Company”) for the quarter ended June 30, 2026 and the year to date results for the period January 01, 2026 to June 30, 2026, the Unaudited Statement of Assets and Liabilities as on that date and the Unaudited Statement of Cash Flows for the half-year ended on that date which are included in the accompanying ‘Statement of Unaudited Financial Results for the quarter and half year ended June 30, 2 [Showing first 8,000 characters — download PDF for full document]